Loading
Tusamitamab ravtansine was Sanofi's ADC against the classic CEA tumour marker, stopped for futility in lung cancer in 2023.
A CEACAM5-directed ADC with a DM4 maytansinoid payload. Phase 3 CARMEN-LC03 (vs docetaxel in CEACAM5-high non-squamous NSCLC) was stopped in December 2023 when an interim analysis showed the PFS endpoint would not be met; OS was not improved. Sanofi discontinued the whole programme.
Lesson: a tubulin-inhibitor payload at DAR ~4 with a non-permeable release mechanism could not match the TOP1-payload ADC bar set in lung cancer; CEACAM5 itself remains under study with T-cell engagers.
Ball-and-stick model from PubChem 2D record (no 3D conformer available). PubChem record
Humanised anti-CEACAM5 IgG1 with DM4 via cleavable SPDB linker. Connects to CEACAM5.
1.Tusamitamab ravtansine's antibody arm binds CEACAM5 on the surface of the cancer cell.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Tusamitamab ravtansine" OR ABSTRACT:"Tusamitamab ravtansine" OR TITLE:"SAR408701" OR ABSTRACT:"SAR408701") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Tusamitamab ravtansine, not a curated reading list.
Shares Sanofi, Failures are hidden, Non-small-cell lung cancer and the tag failure.
Shares Failures are hidden, Antibody-drug conjugate (ADC) and the tag failure.
Shares Failures are hidden, Antibody-drug conjugate (ADC) and the tag failure.
Shares Failures are hidden and the tag failure.
Shares Failures are hidden and the tag failure.
Shares Failures are hidden, Non-small-cell lung cancer and the tag failure.
Shares Failures are hidden and the tag failure.
Shares Failures are hidden and the tag failure.